ICOpre trademarked in Japan
As part of Iconovos global commercialization plan, we are now strengthening our international IP portfolio by trademarking ICOpre in Japan.…
Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries
Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the…
Iconovo is recruiting as a drive towards increased commercialization
Iconovo is recruiting two new team members to increase the company's commercialization and is now aiming for one to three new signed contracts…
Iconovo and TOA sign agreement for development of a generic product
Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic…
First granted ICOone® patent in China
The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone.
Iconovo…
Iconovo Q3-2021 quarterly report
New nasal inhaler has great potential in treatment of COVID-19
Key figures in TSEK unless otherwise indicated
Jul-Sep 2021
Jul-Sep 2020
Jan-Sep…
Meet Iconovo at Bio-Europe Digital
Iconovo will participate at Bio-Europe Digital, an online event that will be held 25-28 October. Here we will present ICOone - our disposable single-dose…
Iconovo develops inhaled Covid-19 vaccine
BBC, and a line of other media channels, has acknowledged Iconovo and its groundbreaking work with immunotherapy company ISR for the development of inhaled…
Iconovo will participate at CPhI Milan
Iconovo will participate at the CPhI event in Milan Italy, 9-11 November 2021. Here thousands of pharma suppliers and buyers unite, connect and do business.…
ICOpre – the story behind a new, generic inhaler platform to Ellipta
Iconovo has developed a new and innovative dry powder inhaler platform - ICOpre - aimed for a global market. ICOpre is a pre-metered dry powder inhaler…